16:42 , Oct 26, 2018 |  BC Week In Review  |  Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright,...
18:23 , Oct 23, 2018 |  BC Extra  |  Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China...
23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
22:36 , Jan 5, 2018 |  BC Week In Review  |  Company News

Ambrx gets Chinese rights to Tracon's carotuximab

Cancer company Tracon Pharmaceuticals Inc. (NASDAQ:TCON) granted Ambrx Inc. (La Jolla, Calif.) exclusive rights to develop and commercialize carotuximab (IV TRC105) in China, Hong Kong, Macau and Taiwan for all indications excluding ophthalmology, which are...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest FGF21 could help treat spinal cord damage associated with traumatic brain injury (TBI) and multiple sclerosis. In postmortem tissue samples from MS patients, levels of the FGF21 signaling marker...
14:37 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Additional Ph II data

Additional data from a double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 for 16 weeks...
02:34 , Apr 24, 2017 |  BC Extra  |  Clinical News

NGM, BMS add to NASH data

Newly released data from a Phase II study of NGM282 from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) to treat non-alcoholic steatohepatitis showed that 3 and 6 mg doses of the candidate increased LDL levels...
19:18 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Ph II data

A double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 each met the primary endpoint of...
22:41 , Apr 5, 2017 |  BC Extra  |  Clinical News

New NASH readouts for NGM, Bristol

New data showed that fibroblast growth factor (FGF) analogs from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) each reduced liver fat in separate Phase II studies to treat non-alcoholic steatohepatitis....
22:05 , Jan 6, 2017 |  BC Week In Review  |  Company News

Ambrx, MabSpace deal

Ambrx and MabSpace partnered exclusively to discover and develop oncology antibody drug conjugates (ADCs). The partners will use MabSpace's humanized antibody technology in combination with Ambrx's EuCode conjugation platform. The partners said they will share...